Listen
LEDAGA (chlormethine), alkylating agent
ONCOLOGY - New medicinal product
Opinions on drugs -
Posted on
Oct 04 2017
Reason for request
Inclusion
No clinical benefit demonstrated in the topical treatment of mycosis fungoides by comparison with CARYOLYSINE.
- LEDAGA has marketing authorisation in the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma in adults.
- LEDAGA gel has the same active ingredient (chlormethine) and the same indication as CARYOLYSINE cutaneous solution.
- The non-inferiority of LEDAGA compared with a chlormethine-based preparation has been demonstrated.
Clinical Benefit
| Substantial |
- |
Clinical Added Value
| no clinical added value |
- |
Therapeutic use
|
- |
English version
Contact Us
Évaluation des médicaments
